| 000 | 01388 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250517215136.0 | ||
| 264 | 0 | _c20181015 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1099-0801 | ||
| 024 | 7 |
_a10.1002/bmc.4290 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFlint, Robert B | |
| 245 | 0 | 0 |
_aSimultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and keto-doxapram in plasma using liquid chromatography-tandem mass spectrometry. _h[electronic resource] |
| 260 |
_bBiomedical chromatography : BMC _cOct 2018 |
||
| 300 |
_ae4290 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Observational Study | ||
| 650 | 0 | 4 |
_aCefazolin _xblood |
| 650 | 0 | 4 |
_aChromatography, High Pressure Liquid _xmethods |
| 650 | 0 | 4 |
_aDoxapram _xblood |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 |
_aFentanyl _xanalogs & derivatives |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aLimit of Detection |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 |
_aTandem Mass Spectrometry _xmethods |
| 700 | 1 | _aBahmany, Soma | |
| 700 | 1 | _avan der Nagel, Bart C H | |
| 700 | 1 | _aKoch, Birgit C P | |
| 773 | 0 |
_tBiomedical chromatography : BMC _gvol. 32 _gno. 10 _gp. e4290 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/bmc.4290 _zAvailable from publisher's website |
| 999 |
_c28398423 _d28398423 |
||